MHM Magazine

Issue 61 | 2022 | MENTAL HEALTH MATTERS | 47 MHM Significant reduction in depressive symptoms; 1 comparable to SSRIs 2 More effective in major depressive disorder with painful physical symptoms, than SSRIs 2 Guideline-recommended first-line therapy for diabetic peripheral neuropathic pain 3 Well-balanced inhibitor of serotonin and noradrenaline reuptake 4 S5 DUZELA 30 mg hard gastro-resistant capsules. Each capsule contains 30 mg duloxetine (as hydrochloride). Contains sugar (sucrose and mannitol). Pharmacological classification: A 1.2 Psychoanaleptics (antidepressants). Reg. No. 48/1.2/0680. S5 DUZELA 60 mg hard gastro-resistant capsules. Each capsule contains 60 mg duloxetine (as hydrochloride). Contains sugar (sucrose and mannitol). Pharmacological classification: A 1.2 Psychoanaleptics (antidepressants). Reg. No. 48/1.2/0681. Applicant: Ranbaxy Pharmaceuticals (Pty) Ltd, 14 Lautre Road, Stormill, Ext.1, Roodepoort, 1724. Tel: +27 11 495-0100 . Fax: +27 12 495-0150 . www.sunpharma.com References: 1. Harada E, Tokouka H, Fujikoshi S, et al. Is duloxetine’s effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms: Pooled analyses of three randomized controlled trials. Pain 2016;157:577-584. 2. Kuga A, Tsuji T, Hayashi S, et al. An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis. Neuropsychiatric Disease & Treatment 2017;13:2105-2114. 3. Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clinical Therapeutics 2018;40(6):828-849. 4. Muneoka K. Pharmacotherapy of major depressive disorder: Focus on duloxetine. Clinical Medicine: Therapeutics 2009;1:1541-1556. 5. Data on file. Bioequivalence study of duloxetine. SSRI – selective serotonin reuptake inhibitor Restore the Balance & of Mind Body Bioequivalent to the originator 5